Skip to content
Search

Latest Stories

Negotiations on CPCF arrangements for 2022/23 begin

The tripartite negotiations to set the arrangements for the Community Pharmacy Contractual Framework (CPCF) in 2022/23 – Year 4 of the five-year CPCF deal – have now begun, the Pharmaceutical Services Negotiating Committee (PSNC) said.

The discussions, beginning ahead of the start of the financial year, are taking place between the PSNC and the Department of Health and Social Care (DHSC) and the NHS England and NHS Improvement (NHSE&I).


It will cover issues related to service, funding and other arrangements for pharmacies in 2022/23, in line with the five-year CPCF deal.

The three entities will also discuss the progress made to date, which has been partly impacted by the Covid-19 pandemic, and the recent joint Annual Review process, where PSNC raised serious concerns around the available capacity within community pharmacy.

The negotiator stated that all parties recognise the contribution of community pharmacies towards the healthcare in the first three years of the five-year CPCF deal.

It added that the PSNC is committed to work to embed community pharmacies, and expand their role within wider NHS systems.

Bharat Patel, PSNC vice-chair and negotiating team member, and an independent community pharmacy contractor, said: “As we approach the end of Year 3 of the five-year CPCF arrangements, many contractors find themselves in an extremely difficult situation trying to balance spiralling costs, capacity pressures and the increasing workforce issues. Some of the immediate pressures of Covid-19 may appear to have gone away, but like most of the health service, pharmacies are not feeling any relief.

“PSNC’s Negotiating Team worked hard through the recent Annual Review process to show government and the NHS the reality facing community pharmacies. We set out our serious concerns around the capacity available in the absence of planned efficiency gains, and about the unsustainable efficiencies that the past two years have required of the sector.

“We have been clear that without the injection of additional funding, capacity is unlikely to be able to grow, particularly at a time of accelerated pressures on staffing.

He noted that though the Spending Review showed a funding uplift is not possible, but “we must continue to make a strong case for investment in the sector, and to seek fair funding for the walk-in advice that so many people are relying on from pharmacies.

“We are actively gathering evidence as we begin what we expect, once again, to be very challenging discussions.”

Andrew Lane Andrew Lane, chair, NPA

Commenting on the funding needs, the National Pharmacy Association (NPA) chair Andrew Lane, said: “We understand why this will be a challenging round of negotiations, but all parties should proceed on the basis that pharmacies provide vital services and deliver for the NHS in a cost-effective way.

“It’s time to end the years of underfunding in England and instead invest in pharmacies to meet the growing healthcare needs of the population.”

The PSNC informed that these negotiations will remain confidential but it will update contractors on the outcomes of these discussions.

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less